vx-745 has been researched along with Adjuvant Arthritis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balagué, C; Caturla, F; Domínguez, M; Esteve, C; Godessart, N; Huerta, JM; Lumeras, W; Orellana, A; Roca, R; Vidal, B; Vidal, L | 1 |
| Balagué, C; Caturla, F; Domínguez, M; Lumeras, W; Maldonado, M; Orellana, A; Segarra, V; Vidal, B; Vidal, L | 1 |
| Allémann, E; Doelker, E; Gabay, C; Jordan, O; Maudens, P; Pradal, J; Seemayer, CA; Waldburger, JM; Zuluaga, MF | 1 |
3 other study(ies) available for vx-745 and Adjuvant Arthritis
| Article | Year |
|---|---|
Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase.
Topics: Aminopyridines; Animals; Arthritis, Experimental; Catalytic Domain; Cell Line; Drug Design; Humans; Inhibitory Concentration 50; Male; Models, Molecular; Oxides; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Rats; Rats, Wistar; Structure-Activity Relationship; Substrate Specificity; Tumor Necrosis Factor-alpha | 2009 |
1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Binding Sites; Cell Line; Crystallography, X-Ray; Humans; Inflammation; Lipopolysaccharides; Male; Mice; Microsomes, Liver; Monocytes; Naphthyridines; p38 Mitogen-Activated Protein Kinases; Protein Binding; Protein Conformation; Rats; Rats, Wistar; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2011 |
Intra-articular bioactivity of a p38 MAPK inhibitor and development of an extended-release system.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Cells, Cultured; Chemistry, Pharmaceutical; Delayed-Action Preparations; Diffusion; Drug Carriers; Humans; Injections, Intra-Articular; Joints; Kinetics; Male; Mice, Inbred C57BL; p38 Mitogen-Activated Protein Kinases; Particle Size; Polymers; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Solubility; Synovial Membrane; Technology, Pharmaceutical | 2015 |